Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.
Chang JE, McQuinn D, Hyun M, Kim K, Kenkre VP, Rajguru SA, Pophali PA, Endres M, Howard M, Wassenaar T, Warren RC, Mattison RJ, Wisinski KB, Fletcher CD. Chang JE, et al. Clin Lymphoma Myeloma Leuk. 2024 Oct 9:S2152-2650(24)02358-9. doi: 10.1016/j.clml.2024.09.014. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39477701
VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.
Chang JE, Carmichael LL, Kim K, Peterson C, Yang DT, Traynor AM, Werndli JE, Huie MS, McFarland TA, Volk M, Blank J, Callander NS, Longo WL, Kahl BS. Chang JE, et al. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e61-e67. doi: 10.1016/j.clml.2017.10.006. Epub 2017 Nov 4. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29191715 Free PMC article.
VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.
Chang JE, Peterson C, Choi S, Eickhoff JC, Kim K, Yang DT, Gilbert LA, Rogers ES, Werndli JE, Huie MS, McFarland TA, Volk M, Blank J, Callander NS, Longo WL, Kahl BS. Chang JE, et al. Br J Haematol. 2011 Oct;155(2):190-7. doi: 10.1111/j.1365-2141.2011.08820.x. Epub 2011 Aug 16. Br J Haematol. 2011. PMID: 21848883 Free PMC article. Clinical Trial.
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
Chang JE, Havighurst T, Kim K, Eickhoff J, Traynor AM, Kirby-Slimp R, Volk LM, Werndli J, Go RS, Weiss M, Blank J, Kahl BS. Chang JE, et al. Br J Haematol. 2016 Apr;173(2):283-91. doi: 10.1111/bjh.13957. Epub 2016 Feb 23. Br J Haematol. 2016. PMID: 26913697 Free PMC article. Clinical Trial.
Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial.
Njiaju UO, Tevaarwerk AJ, Kim K, Chang JE, Hansen RM, Champeny TL, Traynor AM, Meadows S, Van Ummersen L, Powers K, Stewart JA. Njiaju UO, et al. Among authors: chang je. Cancer Chemother Pharmacol. 2013 Mar;71(3):613-8. doi: 10.1007/s00280-012-2044-2. Epub 2012 Dec 11. Cancer Chemother Pharmacol. 2013. PMID: 23228989 Free PMC article. Clinical Trial.
242 results